- Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms
- The report discusses the company’s ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories
- Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures
- These programs position the company for entry into collaborative opportunities to support further growth and provide growth capital
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://ibn.fm/XI5mO). The report considers the potential approval and commercialization of products processed with the company’s patented DehydraTECH(TM) drug delivery platform technology that increases drug bioavailability, and ongoing research and development (“R&D”) activities, including recent revelations that the platform technology may offer a new mechanism of action, to support a $14.00 share valuation (https://ibn.fm/Q4rQJ).
“DehydraTECH offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels and AUC (area under the curve), brain permeation, taste masking, and side effect reduction. As DehydraTECH does not employ a covalent bond, [it] is not a new molecular entity and can rely on previously conducted safety and efficacy data to obtain regulatory approval,” the report reads.
The report highlights the company’s accomplishments during the current financial year 2023, which began September 1, 2022, acknowledging the considerable ground Lexaria has traversed with its research and development (“R&D”) activities. For example, the lead R&D program seeks to investigate DehydraTECH-processed cannabidiol (“CBD”) for the treatment of hypertension; five human clinical trials have been conducted to date, yielding positive results.
These results come amid increasing interest from big pharma. In early 2023, for instance, AstraZeneca (NASDAQ: AZN) initiated a bid to acquire CinCor Pharma, Inc., a US-based clinical-stage biopharmaceutical company developing novel treatment for resistant and uncontrolled hypertension as well as chronic kidney disease. Though the bid is yet to be accepted, according to a disclaimer on AstraZeneca’s website (https://ibn.fm/E0Hxh), the juggernaut’s interest, Zacks’ report explains, “accentuates the unmet need for effective control of hypertension and provides a healthy backdrop for further work by Lexaria in this area.”
This additional work comes in the form of an expected Food and Drug Administration (“FDA”)-approved Phase 1b clinical study. Accordingly, Lexaria intends to submit its Investigational New Drug (“IND”) application for the hypertension program mid-year, with the study expected to commence in the second half of the year, according to the report.
In addition, Lexaria’s efficient use of capital has allowed it to expand its R&D into new preclinical work, including efforts evaluating DehydraTECH-CBD as a potential treatment for diabetes, dementia, and seizures. And as is synonymous with all its R&D programs, these efforts are not only strategic but also influenced by an ever-present market need.
The company took an interest in the seizure space following the FDA’s approval of GW Pharmaceuticals’ Epidiolex, acquired by Jazz Pharmaceuticals, a CBD oral solution for the treatment of seizures in children with Lennox-Gastaut or Dravet syndrome. This marked the first time a drug containing an active ingredient from the cannabis plant had received approval. With regulatory approval in the bag, Epidiolex would go on to generate $750 million in revenues in 2022, a figure that will likely increase to over $1 billion by 2024. This success spurred Lexaria to perform its own studies evaluating the efficacy of DehydraTECH-CBD for seizures. In results released in November last year, the company established that DehydraTECH-CBD worked faster and better at lower doses than Epidiolex (https://ibn.fm/svWzC).
Regarding dementia, the report underlines that although there are several approved drugs, they have had limited benefits, lacked the clear-cut benefit desired, or resulted in adverse side effects. “This leaves the dementia field wide open for therapies that can either slow or improve the symptoms of dementia,” the report continues. For its part, Lexaria intends to capitalize on this gap and has initiated a study evaluating the potential therapeutic use of DehydraTECH-CBD in dementia.
The company is also evaluating other DehydraTECH-processed candidates, including oral nicotine, antivirals, PDE5 inhibitors, hormones, and more. Of these focus areas, the report projects penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories.
“While still early stage, these programs could be excellent partnership opportunities that will support further growth and potentially provide growth capital,” the report concludes.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.comw
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
